查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1702363

全球癌症诊断市场 - 2025-2033

Global Cancer Diagnostics Market - 2025-2033
出版日期: | 出版商: DataM Intelligence | 英文 176 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

2024 年全球癌症诊断市场规模达到 217.1 亿美元，预计到 2033 年将达到 426.4 亿美元，在 2025-2033 年预测期内的复合年增长率为 8.7%。

全球癌症诊断市场涵盖专注于检测和诊断各种类型癌症（尤其是早期癌症）的医疗设备、工具、技术和服务的行业。该市场包括广泛的诊断解决方案，例如影像方法（例如，MRI、CT 扫描、PET 扫描）、分子和基因测试（例如，下一代定序、液体活检）、病理学测试和有助于识别癌症相关生物标记的筛检技术。

这些诊断工具的主要目的是提供准确、及时的癌症检测，从而提供更有效、个人化的治疗方案，并最终改善患者的治疗效果和存活率。癌症盛行率的不断上升、诊断技术的不断进步以及对早期检测和个人化癌症治疗的需求不断增加推动了市场的发展。

市场动态：

驾驶员和约束装置

癌症发生率和盛行率上升

癌症发病率和盛行率的上升极大地推动了癌症诊断市场的成长，预计在预测期内将继续推动市场的发展。例如，根据2022年Globocon的资料，男性癌症发生率为1,030万，女性为970万。 2025年，预计男性癌症发生人数将达1,250万，女性癌症发生人数将达1,160万。发病率的不断上升凸显了对可获得且经济高效的癌症诊断解决方案的迫切需求。

全球人口老化导致癌症风险增加，因为老年人更容易罹患癌症。这种人口结构的变化导致癌症病例增加，凸显了对能够在早期发现癌症的诊断测试的需求日益增长，最终改善治疗效果。

因此，癌症病例的增加直接推动了对癌症诊断的需求，从而带动相关产品和服务的市场不断增长。这包括对于识别和监测不同类型癌症至关重要的诊断测试、影像系统和实验室服务。这些趋势迫切需要先进的诊断技术，推动市场成长，并强调解决全球癌症治疗差距的重要性。

诊断程序和设备成本高昂

诊断程序和设备的高成本是癌症诊断市场成长的重大障碍。一些先进的诊断工具对于早期和准确地发现癌症至关重要，但实施这些工具的高昂费用可能会带来重大挑战。这些工具，例如次世代定序 (NGS)、液体活检和高解析度成像系统，具有直接和间接成本，限制了它们的可及性和广泛使用。

据研究人员称，2021 年初步癌症筛检的年度费用估计为 430 亿美元，低于美国癌症确诊后前 12 个月的年度治疗费用。他们强调，了解癌症筛检成本及其潜在因素对于制定政策决策和指导旨在改善获得推荐癌症筛检服务的计划至关重要。

先进的诊断技术需要大量的前期投资。例如，NGS 系统的成本可能高达数十万美元，而 PET/CT 扫描仪或 MRI 机器等高解析度成像机器的成本可能高达数百万美元。购买这些机器的价格是一个主要障碍，特别是对于中低收入国家的小型医院、诊所或医疗机构。

目录

第一章：市场介绍和范围

  • 报告目标
  • 报告范围和定义
  • 报告范围

第二章：高阶主管见解与关键要点

  • 市场亮点和战略要点
  • 主要趋势和未来预测
  • 按产品分类的片段
  • 按指示摘录
  • 按地区分类的片段

第三章：动态

  • 影响因素
    • 驱动程式
      • 诊断技术的进步
      • 癌症发生率上升
    • 限制
      • 诊断程序和设备成本高昂
      • 发展中地区交通不便
    • 机会
      • 早期检测和筛检项目的成长
    • 影响分析

第四章：战略洞察与产业展望

  • 市场领导者和先驱者
    • 新兴先锋和杰出参与者
    • 拥有最大销售品牌的既定领导者
    • 拥有成熟产品的市场领导者
  • CXO 观点
  • 最新进展与突破
  • 案例研究/正在进行的研究
  • 监管和报销情况
    • 北美洲
    • 欧洲
    • 亚太地区
    • 南美洲
    • 中东和非洲
  • 波特五力分析
  • 供应链分析
  • 专利分析
  • SWOT分析
  • 未满足的需求和差距
  • 市场进入和扩张的推荐策略
  • 情境分析：最佳情况、基本情况和最坏情况预测
  • 定价分析和价格动态
  • 关键意见领袖

第五章：癌症诊断市场（按产品）

  • 耗材
    • 抗体
    • 试剂盒和试剂
    • 探针
    • 其他的
  • 仪器
    • 病理学仪器
      • 组织处理系统
      • 细胞处理器
      • PCR仪器
      • NGS仪器
      • 微阵列
      • 其他的
  • 成像仪器
    • CT系统
    • 超音波系统
    • MRI 系统
    • 乳房X光检查系统
    • 其他的
  • 基于生物标誌物的
  • 切片器械

第六章：癌症诊断市场（依适应症划分）

  • 乳癌
  • 大肠直肠癌
  • 子宫颈癌
  • 肺癌
  • 摄护腺癌
  • 皮肤癌
  • 血癌
  • 肾癌
  • 肝癌
  • 胰腺癌
  • 卵巢癌
  • 其他的

第七章：癌症诊断市场，按区域市场分析和成长机会

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲

第八章：竞争格局与市场定位

  • 竞争概况和主要市场参与者
  • 市占率分析与定位矩阵
  • 策略伙伴关係、併购
  • 产品组合和创新的关键发展
  • 公司基准化分析

第九章：公司简介

  • F. Hoffmann-La Roche Ltd
    • 公司概况
    • 产品组合
      • 产品描述
      • 产品关键绩效指标 (KPI)
      • 历史和预测产品销售
      • 产品销售量
    • 财务概览
      • 公司收入
      • 地区收入份额
      • 收入预测
    • 关键进展
      • 併购
      • 关键产品开发活动
      • 监管部门批准等
    • SWOT分析
  • Abbott.
  • Thermo Fisher Scientific Inc.
  • Siemens Healthcare Private Limited
  • GE HealthCare.
  • Illumina, Inc.
  • Bio-Rad Laboratories, Inc.
  • Hologic, Inc.
  • Koninklijke Philips NV,
  • BD.
  • QIAGEN

第十章：假设与研究方法

  • 资料收集方法
  • 数据三角测量
  • 预测技术
  • 数据验证和确认

第 11 章：附录

简介目录
Product Code: CD1795

The global cancer diagnostics market reached US$ 21.71 billion in 2024 and is expected to reach US$ 42.64 billion by 2033, growing at a CAGR of 8.7% during the forecast period of 2025-2033.

The global cancer diagnostics market encompasses the industry focused on medical devices, tools, technologies, and services used to detect and diagnose various types of cancer, particularly at early stages. This market includes a wide array of diagnostic solutions, such as imaging methods (e.g., MRI, CT scans, PET scans), molecular and genetic tests (e.g., next-generation sequencing, liquid biopsy), pathology tests, and screening techniques that help identify cancer-related biomarkers.

The primary objective of these diagnostic tools is to provide accurate and timely cancer detection, enabling more effective, personalized treatment options and ultimately improving patient outcomes and survival rates. The market is propelled by the growing prevalence of cancer, ongoing advancements in diagnostic technologies, and increasing demand for early detection and personalized cancer care.

Market Dynamics: Drivers & Restraints

Rising Incidence and Prevalence Of Cancer

The rising incidence and prevalence of cancer are significantly driving the growth of the diagnostics for the cancer market and are expected to drive the market over the forecast period. For instance, according to the Globocon data in 2022, the cancer incidence for males was 10.3 million, while for females, it was 9.7 million. By 2025, the cancer incidence is projected to reach 12.5 million for males and 11.6 million for females. This escalating incidence highlights the urgent need for accessible and cost-effective cancer diagnostics solutions.

The aging global population is contributing to a higher risk of cancer, as older individuals are more susceptible to developing the disease. This demographic shift has resulted in a rise in cancer cases, highlighting the increasing demand for diagnostic tests that can detect cancer at earlier stages, ultimately improving treatment outcomes.

As a result, the rising number of cancer cases directly boosts the demand for cancer diagnostics, leading to a growing market for related products and services. This includes diagnostic tests, imaging systems, and laboratory services that are crucial for identifying and monitoring different types of cancer. These trends create a pressing need for advanced diagnostic technologies, fuel market growth, and underscore the importance of addressing disparities in cancer care globally.

High Costs of Diagnostic Procedures and Equipment

High costs of diagnostic procedures and equipment are a significant barrier to the growth of diagnostics for the cancer market. Several advanced diagnostic tools are essential for the early and accurate detection of cancer, but the high expenses associated with their implementation can create significant challenges. These tools, such as next-generation sequencing (NGS), liquid biopsy, and high-resolution imaging systems, come with a combination of direct and indirect costs that limit their accessibility and widespread use.

According to the researchers, the estimated $43 billion annual cost for initial cancer screening in 2021 is lower than the reported annual cost of cancer treatment in the U.S. during the first 12 months following diagnosis. They emphasize that understanding cancer screening costs and their underlying factors is crucial for informing policy decisions and guiding the development of programs aimed at improving access to recommended cancer screening services.

Advanced diagnostic technologies require a substantial upfront investment. For instance, NGS systems can cost hundreds of thousands of dollars, and high-resolution imaging machines like PET/CT scanners or MRI machines can cost millions. The price of purchasing these machines is a major barrier, especially for smaller hospitals, clinics, or healthcare facilities in low- and middle-income countries.

Segment Analysis

The global cancer diagnostics market is segmented based on product, indication, and region.

Product:

The consumables segment in the product is expected to dominate the global cancer diagnostics market with the highest market share

Consumables in cancer diagnostics encompass the single-use or limited-use materials necessary for conducting various diagnostic tests. These items play a critical role in ensuring accurate, reliable, and efficient cancer detection. These items are critical for every step of the diagnostic process, from sample collection and processing to the execution of complex assays.

Consumables are the backbone of the day-to-day operations in cancer diagnostic laboratories. They ensure that every step of the testing process, from sample collection to final analysis, adheres to rigorous quality standards, ultimately improving early detection, treatment planning, and patient outcomes.

Consumables include antibodies, kits & reagents, probes, and other related tools form the foundation of modern cancer diagnostics. They empower clinicians to perform precise, dependable, and increasingly personalized tests, leading to earlier cancer detection and customized treatment strategies for individual patients.

Furthermore, key players in the industry are making innovative launches that would drive this segment's growth in the market. For instance, in August 2024, Oncosure developed and launched a rapid cancer screening test that can detect all types of cancer using just a single blood draw. This indicates that Oncosure has developed and launched an innovative diagnostic tool that rapidly identifies cancer. These factors have solidified the segment's position in the global cancer diagnostics market.

Geographical Analysis

North America is expected to hold a significant position in the global cancer diagnostics market, with the highest market share

North America is expected to hold the largest market share in the global cancer diagnostics market. North America, particularly the United States, has a high cancer prevalence, which fuels the demand for cancer diagnostics solutions.

According to the National Institutes of Health (NIH) data in May 2024, cancer has a significant impact on society both in the United States and globally. Cancer statistics offer insight into the scope of the disease and reflect its burden on society. In 2024, it is estimated that 2,001,140 new cases of cancer will be diagnosed in the United States, and 611,720 people will succumb to the disease. The escalating incidence of cancer underscores the urgent need for cancer diagnostics solutions that are both accessible and cost-effective.

The field of early cancer screening is in dire need of a revolution. Over the next 30 years, more than 40 million Americans are expected to be diagnosed with late-stage cancer, representing 44% of all new cancer diagnoses in the U.S. In this region, a major number of key players are present, including government initiatives, programs, and product approvals that would drive this market growth.

For instance, in February 2024, the National Institutes of Health (NIH) launched the Cancer Screening Research Network (CSRN) to evaluate and advance emerging technologies for cancer screening. This initiative is part of the broader efforts to support the Biden-Harris administration's Cancer Moonshot initiative, which aims to accelerate progress in cancer research and reduce cancer mortality by making significant advances in early detection and treatment.

Also, in August 2024, the Biden-Harris Administration's ARPA-H (Advanced Research Projects Agency for Health) launched a new program aimed at developing an at-home multi-cancer screening test. This initiative is designed to revolutionize the way we detect cancers, especially those that are difficult to diagnose early.

Similarly, in August 2024, Illumina, Inc. announced that the Food and Drug Administration (FDA) had approved its TruSight Oncology (TSO) Comprehensive test as an in vitro diagnostic (IVD) tool, along with its first two companion diagnostic (CDx) indications. This approval marks a significant advancement in cancer diagnostics, providing a valuable tool for both clinicians and patients. Thus, the above factors are consolidating the region's position as a dominant force in the global cancer diagnostics market.

Competitive Landscape

The major global players in the cancer diagnostics market include F. Hoffmann-La Roche Ltd, Abbott, Thermo Fisher Scientific Inc., Siemens Healthcare Private Limited, GE HealthCare, Illumina, Inc., Bio-Rad Laboratories, Inc., Hologic, Inc., Koninklijke Philips N.V., BD, and QIAGEN, among others.

Key Developments

  • In January 2025, Roche received FDA approval for a companion diagnostic-a test designed to identify patients who are most likely to benefit from a specific treatment. In this case, the test determines whether patients with HER2-ultralow metastatic breast cancer are eligible for treatment with ENHERTU.
  • In September 2024, Roche announced an expansion of its digital pathology platform by integrating over 20 advanced AI algorithms from eight new collaborators. Digital pathology involves scanning traditional glass microscope slides and analyzing them using digital tools, including AI, to improve diagnostic accuracy and efficiency.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials and product pipelines and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzed product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: This covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyze competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global cancer diagnostics market report delivers a detailed analysis with 57 key tables, more than 51 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Product
  • 2.4. Snippet by Indication
  • 2.5. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Advancements in Diagnostic Technologies
      • 3.1.1.2. Rising Prevalence of Cancer
    • 3.1.2. Restraints
      • 3.1.2.1. High Costs of Diagnostic Procedures and Equipment
      • 3.1.2.2. Limited Accessibility in Developing Regions
    • 3.1.3. Opportunity
      • 3.1.3.1. Growth in Early Detection and Screening Programs
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with the largest-selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. CXO Perspectives
  • 4.3. Latest Developments and Breakthroughs
  • 4.4. Case Studies/Ongoing Research
  • 4.5. Regulatory and Reimbursement Landscape
    • 4.5.1. North America
    • 4.5.2. Europe
    • 4.5.3. Asia Pacific
    • 4.5.4. South America
    • 4.5.5. Middle East & Africa
  • 4.6. Porter's Five Forces Analysis
  • 4.7. Supply Chain Analysis
  • 4.8. Patent Analysis
  • 4.9. SWOT Analysis
  • 4.10. Unmet Needs and Gaps
  • 4.11. Recommended Strategies for Market Entry and Expansion
  • 4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.13. Pricing Analysis and Price Dynamics
  • 4.14. Key Opinion Leaders

5. Cancer Diagnostics Market, By Product

  • 5.1. Introduction
    • 5.1.1. Analysis and Y-o-Y Growth Analysis (%), By Product
    • 5.1.2. Market Attractiveness Index, By Product
  • 5.2. Consumables*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 5.2.3. Antibodies
    • 5.2.4. Kits & Reagents
    • 5.2.5. Probes
    • 5.2.6. Others
  • 5.3. Instruments
    • 5.3.1. Pathology-based Instruments
      • 5.3.1.1. Tissue Processing Systems
      • 5.3.1.2. Cell Processors
      • 5.3.1.3. PCR Instruments
      • 5.3.1.4. NGS Instruments
      • 5.3.1.5. Microarrays
      • 5.3.1.6. Others
  • 5.4. Imaging Instruments
      • 5.4.1.1. CT Systems
      • 5.4.1.2. Ultrasound Systems
      • 5.4.1.3. MRI Systems
      • 5.4.1.4. Mammography Systems
      • 5.4.1.5. Others
  • 5.5. Biomarker-Based
  • 5.6. Biopsy Instruments

6. Cancer Diagnostics Market, By Indication

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 6.1.2. Market Attractiveness Index, By Indication
  • 6.2. Breast Cancer*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Colorectal Cancer
  • 6.4. Cervical Cancer
  • 6.5. Lung Cancer
  • 6.6. Prostate Cancer
  • 6.7. Skin Cancer
  • 6.8. Blood Cancer
  • 6.9. Kidney Cancer
  • 6.10. Liver Cancer
  • 6.11. Pancreatic Cancer
  • 6.12. Ovarian Cancer
  • 6.13. Others

7. Cancer Diagnostics Market, By Regional Market Analysis and Growth Opportunities

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 7.1.2. Market Attractiveness Index, By Region
  • 7.2. North America
    • 7.2.1. Introduction
    • 7.2.2. Key Region-Specific Dynamics
    • 7.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 7.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 7.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 7.2.5.1. U.S.
      • 7.2.5.2. Canada
      • 7.2.5.3. Mexico
  • 7.3. Europe
    • 7.3.1. Introduction
    • 7.3.2. Key Region-Specific Dynamics
    • 7.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 7.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 7.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 7.3.5.1. Germany
      • 7.3.5.2. U.K.
      • 7.3.5.3. France
      • 7.3.5.4. Spain
      • 7.3.5.5. Italy
      • 7.3.5.6. Rest of Europe
  • 7.4. South America
    • 7.4.1. Introduction
    • 7.4.2. Key Region-Specific Dynamics
    • 7.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 7.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 7.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 7.4.5.1. Brazil
      • 7.4.5.2. Argentina
      • 7.4.5.3. Rest of South America
  • 7.5. Asia-Pacific
    • 7.5.1. Introduction
    • 7.5.2. Key Region-Specific Dynamics
    • 7.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 7.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 7.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 7.5.5.1. China
      • 7.5.5.2. India
      • 7.5.5.3. Japan
      • 7.5.5.4. South Korea
      • 7.5.5.5. Rest of Asia-Pacific
  • 7.6. Middle East and Africa
    • 7.6.1. Introduction
    • 7.6.2. Key Region-Specific Dynamics
    • 7.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 7.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication

8. Competitive Landscape and Market Positioning

  • 8.1. Competitive Overview and Key Market Players
  • 8.2. Market Share Analysis and Positioning Matrix
  • 8.3. Strategic Partnerships, Mergers & Acquisitions
  • 8.4. Key Developments in Product Portfolios and Innovations
  • 8.5. Company Benchmarking

9. Company Profiles

  • 9.1. F. Hoffmann-La Roche Ltd*
    • 9.1.1. Company Overview
    • 9.1.2. Product Portfolio
      • 9.1.2.1. Product Description
      • 9.1.2.2. Product Key Performance Indicators (KPIs)
      • 9.1.2.3. Historic and Forecasted Product Sales
      • 9.1.2.4. Product Sales Volume
    • 9.1.3. Financial Overview
      • 9.1.3.1. Company Revenue
      • 9.1.3.2. Geographical Revenue Shares
      • 9.1.3.3. Revenue Forecasts
    • 9.1.4. Key Developments
      • 9.1.4.1. Mergers & Acquisitions
      • 9.1.4.2. Key Product Development Activities
      • 9.1.4.3. Regulatory Approvals, etc.
    • 9.1.5. SWOT Analysis
  • 9.2. Abbott.
  • 9.3. Thermo Fisher Scientific Inc.
  • 9.4. Siemens Healthcare Private Limited
  • 9.5. GE HealthCare.
  • 9.6. Illumina, Inc.
  • 9.7. Bio-Rad Laboratories, Inc.
  • 9.8. Hologic, Inc.
  • 9.9. Koninklijke Philips N.V.,
  • 9.10. BD.
  • 9.11. QIAGEN

LIST NOT EXHAUSTIVE

10. Assumptions and Research Methodology

  • 10.1. Data Collection Methods
  • 10.2. Data Triangulation
  • 10.3. Forecasting Techniques
  • 10.4. Data Verification and Validation

11. Appendix

  • 11.1. About Us and Services
  • 11.2. Contact Us